Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

lamotrigine

Drug and asset intelligence for lamotrigine with 20 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 14
Catalysts: 6
Stage: Development stage unavailable

Sponsor company

Aurobindo Pharma →

Recent signals(14)

ClinicalAugust 5, 2026

KarXT Study for Bipolar-I Disorder Mania Shows Potential Efficacy

A study is underway to assess the efficacy and safety of adjunctive KarXT in treating mania in Bipolar-I Disorder patients.

RegulatoryAugust 3, 2026

FDA Approves Lamotrigine Supplement Application by Taro

The FDA has approved a supplemental application for lamotrigine submitted by Taro.

StrategyJuly 30, 2026

FDA Approves Lamotrigine ANDA206382 Submission by Sciegen Pharmaceuticals

The FDA has accepted the Abbreviated New Drug Application (ANDA) for lamotrigine submitted by Sciegen Pharmaceuticals.

RegulatoryJuly 28, 2026

FDA Accepts Lamotrigine Supplement Application from Glenmark

The FDA has accepted a supplemental application for Lamotrigine from Glenmark Pharmaceuticals.

RegulatoryJuly 26, 2026

FDA Approval Process Update for Lamotrigine by Alembic Pharmaceuticals

Alembic Pharmaceuticals has submitted a supplemental application for Lamotrigine, currently under standard review.

StrategyJuly 26, 2026

FDA Grants AP Status for Lamotrigine ANDA078947 by Torrent Pharmaceuticals

The FDA has granted Abbreviated Approval (AP) status for Torrent Pharmaceuticals' ANDA078947 for Lamotrigine.

StrategyJuly 18, 2026

FDA grants AP status for Lamotrigine ANDA219677 by Taro

The FDA has granted Abbreviated Approval (AP) status for Taro's Lamotrigine ANDA219677.

StrategyJuly 17, 2026

FDA Grants Approval for Lamotrigine ANDA077420 by Rising

The FDA has granted approval for ANDA077420, a generic version of Lamotrigine, submitted by Rising.

StrategyJuly 14, 2026

FDA Approves Lamotrigine ANDA078625 by Rubicon Research

The FDA has approved ANDA078625 for Lamotrigine submitted by Rubicon Research.

StrategyJuly 13, 2026

FDA Grants AP Status for Lamotrigine ANDA079204 by Taro

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Lamotrigine submitted by Taro.

RegulatoryJuly 4, 2026

FDA Approves Lamotrigine Supplement from Glenmark Pharmaceuticals

The FDA has approved a supplement for Lamotrigine submitted by Glenmark Pharmaceuticals.

CompetitiveJuly 3, 2026

FDA Approves Lamotrigine Supplement from Alembic Pharmaceuticals

The FDA has approved a supplemental application for Lamotrigine submitted by Alembic Pharmaceuticals.

RegulatoryJune 7, 2026

Glenmark Pharmaceuticals submits supplemental application for Lamotrigine

Glenmark Pharmaceuticals has submitted a supplemental application for Lamotrigine under ANDA090169, currently under standard review.

StrategyJune 6, 2026

Aurobindo Pharma's Lamotrigine ANDA Submission Receives AP Status

Aurobindo Pharma's ANDA078956 for Lamotrigine has received an Abbreviated Approval (AP) status from the FDA.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(6)

Topline Data

— Lamotrigine

July 17, 2026 · N/A

Topline Data

— Lamotrigine

July 14, 2026 · N/A

Topline Data

Glenmark Pharmaceuticals — Lamotrigine

July 4, 2026 · N/A

Topline Data

Alembic Pharmaceuticals — Lamotrigine

July 3, 2026 · N/A

Topline Data

Glenmark Pharmaceuticals — Lamotrigine

June 7, 2026 · N/A

Topline Data

Aurobindo Pharma — Lamotrigine

June 6, 2026 · N/A

Indications

Bipolar Disorder →

Therapeutic areas

Antiepileptic →

Bipolar Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.